Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that even though diagnosing adults with attention- deficit/hyperactivity disorder (ADHD) is still highly controversial in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), diagnosis and drug-treatment rates for adults are expected to rise within the next ten years.

(Photo: NewsCom: )

"Many adults remain undiagnosed for one of three reasons: 1) they are unable to provide information from their childhood to fulfill the age-of-onset criteria required for a formal diagnosis of ADHD, 2) the diagnosing physician does not believe that ADHD persists into adulthood, or 3) the diagnosing physician does not feel comfortable using criteria based on childhood behaviors in adult patients," said Melissa Garland, analyst at Decision Resources. "However, the experts that we interviewed for this report, especially those in the United Sates, report that the recognition of ADHD as a chronic disorder--and of its persistence into adulthood--is growing."

The report entitled Attention-Deficit/Hyperactivity Disorder also forecasts that Strattera, Eli Lilly's new antidepressant, will quickly penetrate the ADHD market. Approved by the FDA in November 2002, Strattera (atomoxetine) is the first antidepressant specifically indicated for ADHD.

"We expect Strattera to capture as much as 30% of the ADHD market by 2011," continued Ms. Garland. "Although this drug's efficacy is not expected to surpass that of psychostimulants, Strattera will serve as an attractive nonstimulant therapeutic option for physicians who are reluctant to prescribe psychostimulants for ADHD, and for patients who are refractory to or reluctant to use psychostimulants."

Disease Background-Attention-Deficit/Hyperactivity Disorder

Although children exhibiting inattentiveness, impulsivity, and hyperactivity were first described clinically almost a century ago, and drug treatment of these characteristics dates back to 1937, the ADHD market has yet to meet its potential. In 2001, in the world's seven major pharmaceutical markets, approximately 25.4 million children (aged 3-19) and 10.8 million adults (aged 20+) suffered from ADHD, yet the drug-treated population in these countries consisted of only an estimated 4.2 million children and 0.4 million adults.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Attention-Deficit/Hyperactivity Disorder is a Mosaic report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Otsuka's Pletal Will Fuel Major-Market Growth of Vasoactive Treatments

View Now